Pratima S Rao1, Lal P Madathil1, Suresh Rao2, Pushparaja Shetty3, Madhvika Patidar4. 1. Professor, Department of Oral Pathology and Microbiology, Century International Institute of Dental sciences and Research Centre, Kerala University of Health Sciences , Poinachi, Thekkil (Via), Kasaragod, Kerala, India . 2. Head, Radiation Oncology Division, Mangalore Institute of Oncology , Pumpwell, Mangalore, Karnataka, India . 3. Professor & Head, Department of Oral Pathology and Microbiology, A. B. Shetty Memorial Institute of Dental Sciences , Deralakatte, Mangalore, India . 4. Senior Lecturer, Department of Oral Pathology and Microbiology, Babu Banarasi Das College of Dental Sciences , Lucknow, India .
Abstract
AIM: Oral mucositis induced by radiation is an inevitable but transient side-effect of radiotherapy. Acute phase proteins are a class of proteins whose phase concentrations fluctuate in response to inflammation. The best known of the acute phase proteins is C-reactive protein, a protein that rises in the blood with inflammation. MATERIALS AND METHODS: 30 patients undergoing chemo - radiotherapy for head and neck cancer were clinically evaluated for mucositis on day 0, 7, 14, 28 and 42. Blood investigations like C-reactive protein, erythrocyte sedimentation rate and total leukocyte count were also conducted. RESULTS: There was a significant increase in the severity of mucositis during the course of treatment followed by a gradual decrease in severity towards the end of radiotherapy. Comparison of C-reactive protein levels from day 0 to day 42 in the study group showed a significant increase towards the end of radiotherapy. There was a significant increase in erythrocyte sedimentation rate levels till day 14 followed by a decrease towards the end of radiotherapy whereas total leukocyte count showed a significant decrease from day 0 to day 7 followed by an increase towards the end of radiotherapy. CONCLUSION: The oral mucosa bears only a small clinical spectrum of the side-effect conveyed by chemo-radiation. Both widespread and late effects do occur, and tissues may never return to normal completely. Inflammatory serum markers like C-reactive protein, erythrocyte sedimentation rate and total leukocyte count can thus be used as an objective measure to study the complexities of radiation mucositis which is documented as one of the worst side effects of head and neck cancer therapy.
AIM: Oral mucositis induced by radiation is an inevitable but transient side-effect of radiotherapy. Acute phase proteins are a class of proteins whose phase concentrations fluctuate in response to inflammation. The best known of the acute phase proteins is C-reactive protein, a protein that rises in the blood with inflammation. MATERIALS AND METHODS: 30 patients undergoing chemo - radiotherapy for head and neck cancer were clinically evaluated for mucositis on day 0, 7, 14, 28 and 42. Blood investigations like C-reactive protein, erythrocyte sedimentation rate and total leukocyte count were also conducted. RESULTS: There was a significant increase in the severity of mucositis during the course of treatment followed by a gradual decrease in severity towards the end of radiotherapy. Comparison of C-reactive protein levels from day 0 to day 42 in the study group showed a significant increase towards the end of radiotherapy. There was a significant increase in erythrocyte sedimentation rate levels till day 14 followed by a decrease towards the end of radiotherapy whereas total leukocyte count showed a significant decrease from day 0 to day 7 followed by an increase towards the end of radiotherapy. CONCLUSION: The oral mucosa bears only a small clinical spectrum of the side-effect conveyed by chemo-radiation. Both widespread and late effects do occur, and tissues may never return to normal completely. Inflammatory serum markers like C-reactive protein, erythrocyte sedimentation rate and total leukocyte count can thus be used as an objective measure to study the complexities of radiation mucositis which is documented as one of the worst side effects of head and neck cancer therapy.
Authors: M J Dodd; C Miaskowski; G H Shiba; S L Dibble; D Greenspan; L MacPhail; S M Paul; P Larson Journal: Cancer Invest Date: 1999 Impact factor: 2.176
Authors: B Maciejewski; A Zajusz; B Pilecki; J Swiatnicka; K Skladowski; W Dorr; J Kummermehr; K R Trott Journal: Radiother Oncol Date: 1991-09 Impact factor: 6.280
Authors: J W Denham; L J Peters; J Johansen; M Poulsen; D S Lamb; A Hindley; P C O'Brien; N A Spry; M Penniment; H Krawitz; S Williamson; J Bear; L Tripcony Journal: Radiother Oncol Date: 1999-08 Impact factor: 6.280
Authors: M A Stokman; F K L Spijkervet; H M Boezen; J P Schouten; J L N Roodenburg; E G E de Vries Journal: J Dent Res Date: 2006-08 Impact factor: 6.116
Authors: Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg Journal: Radiother Oncol Date: 2003-03 Impact factor: 6.280
Authors: Ana Gabriela Costa Normando; Camila Lopes Rocha; Isabela Porto de Toledo; Paulo Tadeu de Souza Figueiredo; Paula Elaine Diniz Dos Reis; Graziela De Luca Canto; Eliete Neves Silva Guerra Journal: Support Care Cancer Date: 2017-06-16 Impact factor: 3.603
Authors: Claudio Pulito; Antonio Cristaudo; Caterina La Porta; Stefano Zapperi; Giovanni Blandino; Aldo Morrone; Sabrina Strano Journal: J Exp Clin Cancer Res Date: 2020-10-07